Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Clearside Biomedical Q4 2022 Financial Results and Corporate Update Call Form 10-K View All News Releases Mar 9 2023 Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Feb 23 2023 Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023 Feb 21 2023 Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings View All Events More events are coming soon. View All Stock Quote Change Volume 52 Week High 52 Week Low Apr 2, 2023 1:08 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.